BCL2 and osteosarcoma: Such an option may be supported by the study that was focused on the antiapoptotic BCL2 gene, which emerged transcriptionally to be controlled by EP300 in cardiac myocytes, whereas the CtBP1–p300–FOXO3a complex acts as a transcriptional repressor of the apoptotic regulators Bax and Bim in human osteosarcoma cells [46,47].